1. Scrip
  3. >>Anticancer
  4. >>Immuno-oncology

GlaxoSmithKline Spotlights Immune System And Oncology R&D

Two-Year Effort To Refocus Research Pipeline Bearing Fruit

 
• By John Davis

New oncology and immunology products are moving rapidly through GSK’s refocused research pipeline, including new agents for multiple myeloma, endometrial and head and neck cancer, adding to efforts against COVID-19, respiratory syncytial virus infection and HIV/AIDS.  

Lab_Glassware
• Source: Shutterstock

GlaxoSmithKline plc’s latest addition to its immuno-oncology clinical portfolio is an anti-CD96 antibody, GSK6097608, developed in its collaboration with 23andMe, Inc.., which has just entered Phase I studies, according to the company’s chief scientific officer Hal Barron.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer